Related references
Note: Only part of the references are listed.Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2
E. Ferrante et al.
ENDOCRINE-RELATED CANCER (2006)
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours
Erika Hubina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
RA Feelders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
M Biswas et al.
CLINICAL ENDOCRINOLOGY (2005)
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly
JS Bevan
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria
CL Ronchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
P Petrossians et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
SW van Thiel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis
P Dasgupta
PHARMACOLOGY & THERAPEUTICS (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia
A Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cardiovascular function in acromegaly
RN Clayton
ENDOCRINE REVIEWS (2003)
Somatostatin analogs in medical treatment of acromegaly
MS Racine et al.
ENDOCRINE (2003)
Guidelines for acromegaly management
S Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly
P Epaminonda et al.
CLINICAL ENDOCRINOLOGY (2001)
Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: clinical implications
P Caron et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000)
Criteria for cure of acromegaly: A consensus statement
A Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
